the effect of magnesium sulfate versus dexmedetomidine as an adjuvant to ropivacaine on analgesia in supraclavicular block under ultrasound guidance

Comparing the effect of magnesium sulfate versus dexmedetomidine as an adjuvant to ropivacaine on analgesia in supraclavicular block under ultrasound guidance

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250730066698N1

Enrollment

Registered

2025-07-31

Start date

2025-08-23

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient candidate for elective surgery for upper limb fracture.

Interventions

Intervention 1: First intervention group: Magnesium sulfate group, which will receive 33 cc of 0.5% ropivacaine plus 150 mg of 20% magnesium sulfate. Intervention 2: Second intervention group: Dexmede

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients aged 18 to 70 years who are candidates for elective upper limb surgery Absence of neurological or neuromuscular diseases, coagulation disorders, morbid obesity, septicemia, and local infection at the site of the block No known allergies to ropivacaine, magnesium sulfate, and dexmedetomidine.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Patients' pain after removal of sensory and motor block during surgery. Timepoint: In recovery as time zero and then 1, 6, 12 and 24 hours after surgery. Method of measurement: Visual Analog Scale (VAS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadali Khayami

Ahvaz University of Medical Sciences

mohammadalikhayami66@gmail.com+98 61 3292 3985

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026